Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.
Steven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.
Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.
Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.
Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).
Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.
Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid–based therapies in acute myeloid leukemia.
Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.
Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.
Karyn A. Goodman, MD, radiation oncologist, professor in the Department of Radiation Oncology, University of Colorado Denver, discusses ongoing trials in the field of radiation oncology.
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.
Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.
Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.
J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.
Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.
Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.
Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.
Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.
Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.
Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.
Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.
Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.
Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.
Gargi D. Basu, PhD, senior director of Clinical Curation, Ashion Analytics, discusses a study that examined alterations in the cell cycle checkpoint pathway in patients with breast cancer.
Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.
Sanaz Memarzadeh, MD, PhD, associate professor of Obstetrics and Gynecology, and the director of the Gynecologic Oncology Discovery Lab at UCLA, discusses her preclinical research on resistant tumor cells in ovarian cancer.
Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.
Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors.
